Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 8 Years

被引：0
|
作者：
Wollenhaupt, Juergen [1 ]
Silverfield, Joel [2 ]
Lee, Eun Bong [3 ]
Terry, Ketti [4 ]
Kwok, Kenneth [5 ]
Abramsky, Staci [5 ]
Wang, Min [5 ]
Nduaka, Chudy [6 ]
DeMasi, Ryan [5 ]
Wang, Lisy [4 ]
机构：
[1] Univ Hamburg, Eilbek Teaching Hosp, Schoen Klin Hamburg, Hamburg, Germany
[2] Healthpoint Med Grp, Tampa, FL USA
[3] Seoul Natl Univ, Seoul, South Korea
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Inc, Collegeville, PA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1647
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
    Curtis, Jeffrey R.
    Wollenhaupt, Juergen
    Chatzidionysiou, Katerina
    Tas, Sander W.
    Wang, Lisy
    Shi, Harry
    Montoro, Maria
    Neregard, Petra
    Dahl, Palle
    Tsekouras, Vassilis
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [32] Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment
    Lichtenstein, G. R.
    Loftus, E. V., Jr.
    Wei, S. C.
    Damiao, A. O.
    Judd, D.
    Lawendy, N.
    Chan, G.
    Zhang, H.
    Wang, W.
    Thorpe, A. J.
    Bloom, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S100 - S101
  • [33] Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, in patients with active psoriatic arthritis: Interim data from OPAL Balance, an open label, long-term extension study
    Nash, Peter
    Coates, Laura C.
    Kivitz, Alan J.
    Mease, Philip J.
    Gladman, Dafna D.
    Covarrubias-Cobos, Jose A.
    Kudlacz, Elizabeth
    Menon, Sujatha
    Kanik, Keith S.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB224 - AB224
  • [34] Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
    Fleischmann, Roy
    Yazici, Yusuf
    Wollenhaupt, Juergen
    Wang, Lisy
    Maniccia, Anna
    Kwok, Kenneth
    Takiya, Liza
    van Vollenhoven, Ronald
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [35] SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 24 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: INTERIM DATA FROM OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Nash, P.
    Coates, L. C.
    Kivitz, A. J.
    Mease, P. J.
    Gladman, D. D.
    Covarrubias-Cobos, J. A.
    Fleishaker, D.
    Wang, C.
    Kudlacz, E.
    Menon, S.
    Hendrikx, T.
    Kanik, K. S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 682 - 682
  • [36] TOFACITINIB, AN ORAL JAK INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Bloom, Stuart
    Lichtenstein, Gary R.
    Loftus, Edward V.
    Lawendy, Nervin
    Friedman, Gary S.
    Zhang, Haiying
    Wang, Wenjin
    Thorpe, Andrew J.
    Nduaka, Chudy I.
    Su, Chinyu
    [J]. GUT, 2018, 67 : A62 - A63
  • [37] Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis
    Lloyd-Lavery, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 815 - 816
  • [38] Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study
    Brunner, Hermine, I
    Akikusa, Jonathan D.
    Al-Abadi, Eslam
    Bohnsack, John F.
    Boteanu, Alina Lucica
    Chedeville, Gaelle
    Cuttica, Ruben
    De La Pena, Wendy
    Jung, Lawrence
    Kasapcopur, Ozgur
    Kobusinska, Katarzyna
    Schulert, Grant S.
    Neiva, Claudia
    Rivas-Chacon, Rafael
    Rodriguez, Juan Cruz Rizo
    Vazquez-Del Mercado, Monica
    Wagner-Weiner, Linda
    Weiss, Jennifer E.
    Wouters, Carine
    Posner, Holly
    Wouters, Ann
    Chang, Cheng
    White, Claire
    Kanik, Keith
    Liu, Shixue
    Martini, Alberto
    Lovell, Daniel J.
    Ruperto, Nicolino
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2024,
  • [39] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Mueller, Ruediger B.
    Schulze-Koops, Hendrik
    Furst, Daniel E.
    Cohen, Stanley B.
    Kwok, Kenneth
    Wang, Lisy
    Killeen, Tim
    von Kempis, Johannes
    [J]. CLINICAL RHEUMATOLOGY, 2022, 41 (04) : 1045 - 1055
  • [40] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Ruediger B. Mueller
    Hendrik Schulze-Koops
    Daniel E. Furst
    Stanley B.  Cohen
    Kenneth Kwok
    Lisy Wang
    Tim Killeen
    Johannes von Kempis
    [J]. Clinical Rheumatology, 2022, 41 : 1045 - 1055
12345